Brett Mason (Queensland, Liberal Party, Parliamentary Secretary to the Minister for Health and Ageing) Share this | Hansard source

No. When a new drug comes onto the market—it is not generic; it is a new drug—it is assessed for cost-effectiveness. If it is not cost-effective in terms of its medical efficacy, it will not be listed. There is no reason why the new drugs will be more expensive than those in the United Kingdom or elsewhere.